Please login to the form below

Not currently logged in
Email:
Password:

companion diagnostics

This page shows the latest companion diagnostics news and features for those working in and with pharma, biotech and healthcare.

Gradually, then suddenly

Gradually, then suddenly

The second kept on looking for whole-disease area blockbusters long after companion diagnostics had fractured its market.

Latest news

  • Roche agrees $2.4bn takeover of genomics player Foundation Roche agrees $2.4bn takeover of genomics player Foundation

    Prior to the approval of F1CDx, most companion diagnostics for cancer matched one test to one drug, but the FDA said that using Foundation’s test could identify which patients with ... There has also been movement at the federal level in the US, with

  • Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

    Foundation Medicine is a major player in the emerging field of next generation cancer diagnostics and genomic profiling, and two developments yesterday confirmed it as a leader in what will undoubtedly ... If approved, this test could be the

  • EMA starts firming up its stance on personalised medicines EMA starts firming up its stance on personalised medicines

    The European Medicines Agency (EMA) hopes that when finalised they will help optimise the co-development of medicines and companion diagnostics. ... As diagnostic medical devices, companion diagnostics do not fall within the oversight of the EMA, but the

  • Focus on value: A prescription for pharma Focus on value: A prescription for pharma

    In the long run, companion diagnostics will enable targeting the patients most likely to benefit from a particular therapy.

  • A butterfly flaps its wings A butterfly flaps its wings

    Firstly, deciding rationally who and when it is sensible to treat will be difficult and that creates opportunities for everything from diagnostics to data analytics. ... Secondly, in a world where bang for bucks is everything, single technology

More from news
Approximately 3 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    This encompasses approaches to detecting cancers earlier, including novel techniques such as liquid biopsies (aka circulating tumour DNA tests) and new companion diagnostics.

  • Breakthrough innovation Breakthrough innovation

    The same key agile principles with a different twist. Many pharmaceutical companies are increasingly looking to innovate through the development of companion diagnostics and drug delivery devices, and/or services such ... An optimal innovation approach.

  • Choosing destiny Choosing destiny

    immuno-oncology and companion diagnostics.

  • Harnessing complexity Harnessing complexity

    Companion diagnostics in oncology. As an increasing number of drugs gain approval for patients whose cancers have certain molecular characteristics, the promise of truly personalised medicine is edging closer towards reality. ... This delicate balance

  • Harnessing the power of genetics Harnessing the power of genetics

    Effective use relies on the availability of clinical grade, affordable companion diagnostics in major therapy centres.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Dr Holger Adelmann joins DIA EMEA Dr Holger Adelmann joins DIA EMEA

    In that role he oversaw the reengineering of its clinical biomarker and companion diagnostics business to align with upcoming portfolio demands.

  • FlowMetric Diagnostics names president FlowMetric Diagnostics names president

    FlowMetric Diagnostics, a provider of flow cytometry and cell sorting services, has appointed Amy Williams as its president. ... It is a great time for the development of new flow cytometry-based companion diagnostics which can help advance personalised

  • Roche appoints new oncology research head Roche appoints new oncology research head

    Commenting on Pao's appointment, Reed said: "William is recognised as one of the world's leading molecular oncologists, with world class expertise in targeted cancer therapeutics, translational medicine, molecular diagnostics, ... diagnostics company,

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Tissue Diagnostics Market Promising Growth Opportunities over 2016 to 2026

    Hospitals. Diagnostic laboratories. Research Organizations. Contract Research Organizations. Biotechnology Companies. Tissue Diagnostics Market: Overview. ... Personalized healthcare and companion diagnostics, IVD Development and Digital Pathology and

  • Mastering the precision medicine opportunity

    Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new  FoundationOne CDx, the first and

  • Excellence in oncology: Developing an effective biomarker strategy

    Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and patients.

  • Research Partnership

    Medical devices and diagnostics. Our experience covers everything from insulin pens to large-scale surgical systems. ... Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics